利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

61 条记录 (耗时 0.039 秒)

    Biological Cell Tracking With Ultrasound
    1.
    发明申请
    Biological Cell Tracking With Ultrasound 有权
    超声波生物细胞追踪

    公开(公告)号：US20100158815A1

    公开(公告)日：2010-06-24

    申请号：US12613400

    申请日：2009-11-05

    申请人： Jianjun Wang ,  Flordeliza Villanueva ,  Xucai Chen ,  Andrew Fisher ,  William Richard Wagner

    发明人： Jianjun Wang ,  Flordeliza Villanueva ,  Xucai Chen ,  Andrew Fisher ,  William Richard Wagner

    IPC分类号： A61B8/08

    CPC分类号： A61K49/222 ,  A61B8/481

    摘要： This invention addresses the clinical problem of how to optimize biological cell based therapies, such as stem cell therapy. Currently, cell therapies administered by intravenous, intra-arterial, and/or direct tissue injection are limited by the lack of clinically available imaging methods to detect the in vivo fate of the administered cells. There are many efforts underway to develop imaging strategies for stem cells in vivo, including radionuclide and MRI-based approaches. However, these approaches are limited by potential safety issues (e.g. radioactive exposure of stem cells, toxicity of iron particles used for MRI) and difficulty in serial tracking due to complex instrumentation and/or the requirement for repetitive radiation exposure.

    摘要翻译： 本发明解决了如何优化基于生物细胞的疗法（如干细胞治疗）的临床问题。 目前，通过静脉内，动脉内和/或直接组织注射施用的细胞疗法受到缺乏临床可用的成像方法的限制，以检测所施用细胞的体内命运。 目前正在开展许多努力来开发体内干细胞成像策略，包括放射性核素和基于MRI的方法。 然而，这些方法受到潜在安全问题的限制（例如干细胞的放射性暴露，用于MRI的铁颗粒的毒性）以及由于复杂的仪器和/或对重复辐射暴露的要求而导致的串行跟踪困难。

    Directed cell-based therapy using microbubble tagged cells
    2.
    发明授权
    Directed cell-based therapy using microbubble tagged cells 有权
    使用微泡标记细胞的定向细胞治疗

    公开(公告)号：US08460269B2

    公开(公告)日：2013-06-11

    申请号：US12880807

    申请日：2010-09-13

    申请人： Catalin Toma ,  Flordeliza Villanueva ,  William Richard Wagner ,  Joon S. Lee ,  Jianjun Wang ,  Xucai Chen ,  Andrew Fisher

    发明人： Catalin Toma ,  Flordeliza Villanueva ,  William Richard Wagner ,  Joon S. Lee ,  Jianjun Wang ,  Xucai Chen ,  Andrew Fisher

    IPC分类号： A61M31/00

    CPC分类号： A61M37/0092 ,  A61K35/44 ,  A61N7/022 ,  A61N2007/0039

    摘要： The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and/or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.

    摘要翻译： 所公开的技术描述了可用于提供基于细胞的治疗的组合物和方法。 例如，基于细胞的疗法的一个实施方案涉及损伤组织的再生和/或促进伤口愈合。 某些实施方案通过将生物祖细胞递送到受损组织来提供使用微泡的改进的治疗组合物。 微泡的施用由与包括声学活性气体的微泡的实施方案相互作用的声辐射力引导。 因此，实现了对损伤组织的高效祖细胞传递。 该技术优于药物化合物的靶向递送的一个优点是所递送的祖细胞可能来源于患者（即个体化治疗），从而避免与屈光药物反应相关的副作用，过敏反应和总体问题。

    Intracellular microbubble for imaging an anatomical site
    3.
    发明授权
    Intracellular microbubble for imaging an anatomical site 有权
    用于成像解剖部位的细胞内微泡

    公开(公告)号：US08940277B2

    公开(公告)日：2015-01-27

    申请号：US12613400

    申请日：2009-11-05

    申请人： Jianjun Wang ,  Flordeliza Villanueva ,  Xucai Chen ,  Andrew Fisher ,  William Richard Wagner

    发明人： Jianjun Wang ,  Flordeliza Villanueva ,  Xucai Chen ,  Andrew Fisher ,  William Richard Wagner

    IPC分类号： A61B8/00 ,  A61B8/08 ,  A61K49/22

    CPC分类号： A61K49/222 ,  A61B8/481

    摘要： This invention addresses the clinical problem of how to optimize biological cell based therapies, such as stem cell therapy. Currently, cell therapies administered by intravenous, intra-arterial, and/or direct tissue injection are limited by the lack of clinically available imaging methods to detect the in vivo fate of the administered cells. There are many efforts underway to develop imaging strategies for stem cells in vivo, including radionuclide and MRI-based approaches. However, these approaches are limited by potential safety issues (e.g. radioactive exposure of stem cells, toxicity of iron particles used for MRI) and difficulty in serial tracking due to complex instrumentation and/or the requirement for repetitive radiation exposure.

    摘要翻译： 本发明解决了如何优化基于生物细胞的疗法（如干细胞治疗）的临床问题。 目前，通过静脉内，动脉内和/或直接组织注射施用的细胞疗法受到缺乏临床可用的成像方法的限制，以检测所施用细胞的体内命运。 目前正在开展许多努力来开发体内干细胞成像策略，包括放射性核素和基于MRI的方法。 然而，这些方法受到潜在安全问题的限制（例如干细胞的放射性暴露，用于MRI的铁颗粒的毒性）以及由于复杂的仪器和/或对重复辐射暴露的要求而导致的串行跟踪困难。

    Directed Cell-Based Therapy Using Microbubble Tagged Cells
    4.
    发明申请
    Directed Cell-Based Therapy Using Microbubble Tagged Cells 有权
    使用微泡标记细胞的定向细胞治疗

    公开(公告)号：US20110208113A1

    公开(公告)日：2011-08-25

    申请号：US12880807

    申请日：2010-09-13

    申请人： Catalin Toma ,  Flordeliza Villanueva ,  William Richard Wagner ,  Joon S. Lee ,  Jianjun Wang ,  Xucai Chen ,  Andrew Fisher

    发明人： Catalin Toma ,  Flordeliza Villanueva ,  William Richard Wagner ,  Joon S. Lee ,  Jianjun Wang ,  Xucai Chen ,  Andrew Fisher

    IPC分类号： A61K35/12 ,  A61M37/00 ,  C12N11/00

    CPC分类号： A61M37/0092 ,  A61K35/44 ,  A61N7/022 ,  A61N2007/0039

    摘要： The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and/or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.

    摘要翻译： 所公开的技术描述了用于提供基于细胞的治疗的组合物和方法。 例如，基于细胞的疗法的一个实施方案涉及损伤组织的再生和/或促进伤口愈合。 某些实施方案通过将生物祖细胞递送到受损组织来提供使用微泡的改进的治疗组合物。 微泡的施用由与包括声学活性气体的微泡的实施方案相互作用的声辐射力引导。 因此，实现了对损伤组织的高效祖细胞传递。 该技术优于药物化合物的靶向递送的一个优点是所递送的祖细胞可能来源于患者（即个体化治疗），从而避免与屈光药物反应相关的副作用，过敏反应和总体问题。

    Teleoperation Of Machines Having At Least One Actuated Mechanism And A Fault Detection And Recovery System
    8.
    发明申请
    Teleoperation Of Machines Having At Least One Actuated Mechanism And A Fault Detection And Recovery System 有权
    具有至少一个致动机构和故障检测和恢复系统的机器的远程操作

    公开(公告)号：US20150314447A1

    公开(公告)日：2015-11-05

    申请号：US14649160

    申请日：2013-12-03

    申请人： Biao ZHANG ,  Jianjun WANG ,  George Q. ZHANG ,  Sangeun CHOI ,  Remus BOCA ,  Thomas A. FUHLBRIGGE ,  Thomas GROTH

    发明人： Biao Zhang ,  Jianjun Wang ,  George Q. Zhang ,  Sangeun Choi ,  Remus Boca ,  Thomas A. Fuhlbrigge ,  Tomas Groth

    IPC分类号： B25J9/16

    CPC分类号： B25J9/1689 ,  G05B2219/40195 ,  G05B2219/40204 ,  Y10S901/09 ,  Y10S901/46

    摘要： A machine has at least one actuated mechanism is remotely located from a control station. A two way real-time communication link connects the machine location with the control station. A controller at the machine location has program code that is configured to determine from data from one or more sensors at the machine location if an actual fault has occurred in the machine when the machine is performing its predetermined function and to determine for an actual fault one or more types for the fault and transmit the one or more fault types to the control station for analysis. The code in the controller is configured to be a preprogrammed trap routine specific to the machine function that is automatically executed when an error in machine operation is detected at the machine location. The controller also has a default trap routine that is executed when specific routine does not exist.

    摘要翻译： 机器具有远离控制站的至少一个致动机构。 双向实时通信链路将机器位置与控制站相连。 在机器位置处的控制器具有程序代码，其被配置为从机器位置的一个或多个传感器的数据确定机器是否在机器执行其预定功能时发生实际故障并确定实际故障 或更多类型的故障，并将一个或多个故障类型传输到控制站进行分析。 控制器中的代码被配置为特定于机器功能的预编程陷阱程序，在机器位置检测到机器操作错误时自动执行。 控制器还具有默认的陷阱程序，当特定例程不存在时，它将被执行。

    Method and composition for a protein transduction technology and its applications
    10.
    发明授权
    Method and composition for a protein transduction technology and its applications 有权
    蛋白转导技术的方法和组成及其应用

    公开(公告)号：US08722348B2

    公开(公告)日：2014-05-13

    申请号：US12128320

    申请日：2008-05-28

    申请人： Jianjun Wang ,  Qianqian Li

    发明人： Jianjun Wang ,  Qianqian Li

    IPC分类号： G01N33/567

    CPC分类号： A61K38/00 ,  A61K47/48046 ,  A61K47/48176 ,  C12N15/88 ,  C12P21/00 ,  G01N33/5023 ,  G01N33/58 ,  G01N33/68 ,  G01N2458/15

    摘要： A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein.

    摘要翻译： 发明了用于将外源蛋白有效递送到哺乳动物细胞中的蛋白质转导方法，其具有靶向不同细胞区室的能力并且防止递送的蛋白质从细胞蛋白酶降解。 用于处理蛋白质的组合物在载体中具有阳离子试剂，脂质和增强剂。 该方法可以以多种方式使用，包括：使用哺乳动物细胞机制产生大量正确折叠的翻译后修饰蛋白，使用小分子荧光团进行细胞内荧光光谱和成像，并使用细胞内核磁共振光谱 活哺乳动物细胞。 该方法允许细胞生物学在原子分辨率下与生理和病理相关，并允许蛋白质治疗来治疗人类疾病。 该方法还可用于在哺乳动物细胞内递送外源蛋白质，其中外源蛋白质遵循与内源性蛋白质相似的分泌途径。